Cui C, et al. - This meta-analysis was conducted to analyze the validation and consensus of the clinical application and clinical safety of the new anti-anti-vascular endothelial growth factor (VEGF) drug, conbercept, in the treatment of patients with age-related macular degeneration (AMD). Compared to triamcinolone and traditional transpupillary thermotherapy (TTT), conbercept exerted considerably more positive effects on the long-term best-corrected visual acuity (BCVA) and central retinal thickness (CRT) improvement in AMD patients. In the conbercept group, the serum VEGF level was lower than that in the ranibizumab group.